Join
Live feed
·
INSIDERFilingvia Quantisnow
Keros Therapeutics Inc. logo

Director Knowles Julius sold $28,166 worth of shares (2,625 units at $10.73) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 10,958 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
KROS· Keros Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KROS (Keros Therapeutics Inc.) and more on Quantisnow.